Targeting the endolysosomal host-SARS-CoV-2 interface by clinically licensed functional inhibitors of acid sphingomyelinase (FIASMA) including the antidepressant fluoxetine

The Coronavirus Disease 2019 (COVID-19) pandemic caused by the Severe Acute Respiratory Syndrome Related Coronavirus 2 (SARS-CoV-2) is a global health emergency. As only very limited therapeutic options are clinically available, there is an urgent need for the rapid development of safe, effective, a...

Cijeli opis

Bibliografski detalji

Glavni autori:	Sebastian Schloer, Linda Brunotte, Jonas Goretzko, Angeles Mecate-Zambrano, Nadia Korthals, Volker Gerke, Stephan Ludwig, Ursula Rescher
Format:	Artigo
Jezik:	Inglês
Izdano:	Taylor & Francis Group 2020-01-01
Serija:	Emerging Microbes and Infections
Teme:	SARS-CoV-2 IAV FIASMA fluoxetine viral entry endolysosomal interference
Online pristup:	https://www.tandfonline.com/doi/10.1080/22221751.2020.1829082
Oznake:	Dodaj oznaku Bez oznaka, Budi prvi tko označuje ovaj zapis!